Abstract
Summary: This article presents a review of recent major advances in precision oncology and the future implications of these advances, specifying the iterative progress achieved from the end of 2022 through 2023. We discuss the different classes of precision oncology drugs and associated biomarkers as well as the improvements in clinical trial design that have enabled the efficient testing of these drugs.
Cite
CITATION STYLE
APA
Murciano-Goroff, Y. R., Suehnholz, S. P., Drilon, A., & Chakravarty, D. (2023). Precision Oncology: 2023 in Review. Cancer Discovery, 13(12), 2525–2531. https://doi.org/10.1158/2159-8290.CD-23-1194
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free